Suggestions
Jeffrey Venstrom, M.D.
Chief Medical Officer at GRAIL
Jeffrey Venstrom, M.D. is a prominent physician-scientist currently serving as the Chief Medical Officer at GRAIL.1 His professional focus is on changing how the world understands cancer, as evidenced by his LinkedIn profile description.23
Professional Background
Dr. Venstrom received his medical education from Vanderbilt University School of Medicine.1 His career has been dedicated to advancing cancer research and treatment, with a particular emphasis on innovative approaches to cancer detection and understanding.
Role at GRAIL
As the Chief Medical Officer at GRAIL, Dr. Venstrom plays a crucial role in the company's mission to revolutionize cancer diagnostics. GRAIL is known for its work in developing multi-cancer early detection (MCED) technology.5
Contributions and Collaborations
Dr. Venstrom is actively involved in various aspects of cancer research and awareness:
- He participates in expert discussions and collaborations within the oncology community.2
- He leads efforts to expand real-world evidence in cancer research.3
- Dr. Venstrom is engaged in raising awareness about cancer screening and prevention.4
Research Interests
His work encompasses several key areas:
- Multi-cancer early detection (MCED) technology5
- Collaborations with pharmaceutical companies like AstraZeneca for cancer research6
- Exploration of artificial intelligence applications in healthcare7
Dr. Venstrom regularly shares updates and insights about GRAIL's work and advancements in cancer research through his LinkedIn profile.8 His dedication to changing the landscape of cancer understanding and treatment is evident throughout his professional activities and communications.
Highlights
We are excited to see these new ctDNA data published, with Samsung Medical Center, AstraZeneca, Darren Hodgson, et al; check it out!
This study represents an important contribution to future clinical applications of methylation-based cell-free DNA assays. It provides: ➡️ Additional validation of how circulating tumor DNA (ctDNA) shedding correlates with PET avidity and tumor volume ➡️ Prognostic insights among a large early stage lung population ➡️ New insights on how ctDNA detection correlated with higher PD-L1 expression in tumors
The findings support the possible integration of ctDNA testing into routine diagnostic workflows in early-stage non-small cell #LungCancer (NSCLC). This testing could be particularly useful in identifying high-risk patients who might benefit from innovative treatments. Stay tuned for more, and check out the the full study:
With #ASCO24 wrapping up, I wanted to share a few GRAIL highlights from this year’s congress: ➡️ We showed the potential of adding multi-cancer early detection (MCED) testing to standard-of-care screening for finding cancer recurrence and new primary cancers among cancer survivors ➡️ We also shared data showcasing how adding MCED testing may increase diagnostic efficiency and reduce the time to cancer diagnosis among Medicare patients.
Beyond the expansive exchange of information, every year ASCO provides a valuable opportunity to connect with colleagues across the industry on our shared goal to fight cancer. I’m proud to be part of this team, and looking forward to seeing what we accomplish together next.
